Glooko study sheds light on use of CGM data among diabetes healthcare professionals

Glooko, the leader in diabetes data management, today announced the results of its recent study which examined diabetes healthcare professionals' use of CGM data. The study asked 38 diabetes healthcare professionals (29 endocrinologists; nine diabetes educators) to assess CGM data from 10 people with type 1 diabetes within the Glooko platform. The diabetes healthcare professionals were asked to qualitatively rank each patient's daily glycemic control from "best" to "worst" and indicate which CGM data features were relevant in the ranking process.

  • More than 70% of surveyed clinicians endorsed using three or more CGM data features in assessing glycemic control. This suggests that clinicians value CGM data features which have expanded utility compared to traditional glycemic indicators (SMBG readings, HbA1c) that are static and less dense.
  • Hypoglycemia and variance were the most frequently endorsed CGM data features (89.7% and 82.8% of all participants, respectively).
  • Hyperglycemia (44.8%), time-in- (37.9%) and out-of-range (34.5%), and mean daily glucose levels (24.1%) were also frequently endorsed.
  • No differences were observed between endocrinologists and diabetes educators in how each group assessed CGM data.

Glooko provides a full range of features that enables healthcare professionals to quickly upload and visually analyze CGM data to help create, alter, and optimize patient care plans.

The 27th Annual Scientific and Clinical Congress will be held May 16-20 in Boston. In addition to the poster presentation on May 18 from 5-6:30 pm, Glooko will be showcasing its products in booth 1607 on the exhibition floor.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Diabetes drugs cut asthma attacks by up to 70%, reshaping treatment options